SCHEMBL14745792

SCHEMBL14745792

COC(=O)c1cc2c(n(Cc3ccc(OC)cc3OC)c1=O)-c1ccc(N(C)C)cc1CCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 2/20 0.44
GABRB3 P28472 2/20 0.44
GABRA3 P34903 2/20 0.44
GABRA2 P47869 2/20 0.44
LMNA P02545 3/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 4/20 0.38
MAPT P10636 4/20 0.37
MAPK1 P28482 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C19 P33261 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
USP2 O75604 1/20 0.37
TLR9 Q9NR96 1/20 0.37
GABRA1 P14867 1/20 0.36
F2 P00734 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745682 0.98 GABRG2 (0.44) GABRG2GABRB3GABRA3GABRA2LMNA
SCHEMBL14745374 0.92 TSHR (0.39) LMNATP53TSHRMAPTMAPK1
SCHEMBL14745818 0.90 KMT2A (0.39) LMNATP53TSHRMAPTMAPK1
SCHEMBL14745744 0.85 EGLN1 (0.39) GABRG2GABRB3GABRA3GABRA2LMNA
SCHEMBL14745965 0.83 EGLN1 (0.39) GABRG2GABRB3GABRA3GABRA2TP53
SCHEMBL14745886 0.81 EDNRB (0.41) TSHRMEN1KMT2AALDH1A1EGLN1
SCHEMBL14745679 0.79 GABRG2 (0.37) GABRG2GABRB3GABRA3GABRA2LMNA
SCHEMBL14745574 0.79 EDNRB (0.41) TP53TSHRMAPTMEN1KMT2A
SCHEMBL14745433 0.76 MEN1 (0.39) LMNATP53TSHRMAPTMEN1
SCHEMBL14746068 0.74 AADAT (0.33) GABRG2GABRB3GABRA3GABRA2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP GABRG2 3111/4885GABRB3 2579/4885GABRA3 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.